摘要
目的:探讨与氯丙嗪对精神分裂症疗效有关的D2受体基因的基因型以及其它相关的因素。方法:抽取105例连续住院的精神分裂症患者,给予氯丙嗪≥300mg/d治疗两个月,用PANSS量表评定氯丙嗪疗效,用多聚酶链式反应扩增及限制性片段长度多态性(PCR-RFLPs)技术测定研究对象的基因型和等位基因。所得资料以χ2、t检验及Logistic回归分析。结果:氯丙嗪对精神分裂症的疗效与总病程及D2受体基因的杂合子基因型明显负相关。结论:氯丙嗪对病程越短的精神分裂症患者疗效越好,同时可通过检测D2受体基因的基因型来预测氯丙嗪对精神分裂症的疗效。
Objective:To investigate the relationship between the responses to chlorpromazine for schizophrenic patients and the D 2 receptor gene and the other related factors.Methods:150 inpatients with schizophrenia had been treated by chlorpromazine(≥300mg/d)for 2 months.The responses to chlorpromazine were rated with PANSS(Positive and Negative Symptom Scale)and the genotypes and alleles in these patients were examined with PCR amplification and Restriction Fragment Length Polymorphisms(RFLPs)technique.All the data Were analysised by the χ 2 and t test and the logistic regression analysis.Results:The responses to chlorpromazine for schizophrenic patients are significiantly negatively related to the course and the heterozygote of the D 2 receptor gene.Conclusions:The responses to chlorpromazine for the schizophrenic patients with shorter course are better than those with longer course.Moreover,the D 2 receptor gene can predict the responses to chlorpromazine for schizophrenic patients. [
出处
《中国民政医学杂志》
2000年第2期65-68,共4页
Medical Journal of Chinese Civil Administration
基金
高等学校博士学科点专项科研基金! (编号 9748)
上海医科大学临床学科重点项目基金
